Real World Effectiveness of Antipsychotic Drugs in Patients with Chronic Mental Illness

	*Faculty*
		John W. Newcomer, MD Professor, Psychiatry, Psychology and Medicine Medical Director, Center for Clinical Studies Washington University School of Medicine in St. Louis Dr. Newcomer is the Medical Director for the Center for Clinical Studies at Washington University. Dr. Newcomer is a Principal Investigator on research grants funded through the National Institutes of Health (NIH), and also serves as the Chairman of the Drug Utilization Review (Medicaid) Board for the State of Missouri. Dr. Newcomer has received a number of honors and awards, including a 1999 Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill (NAMI), a 2002 Gerald L. Klerman Award for Outstanding Clinical Research from the National Alliance for Research on Schizophrenia and Depression (NARSAD), and an Independent Scientist Award from the National Institute of Mental Health (NIMH). Funded continuously by the NIH for 14 years, Dr. Newcomer also serves as a reviewer for the NIH as well as other funding agencies, including the Department of Veteran’s Affairs and the National Science Foundation. Dr. Newcomer serves on the editorial board for Neuropsychopharmacology and the Journal of Psychotic Disorders, and he is a reviewer for numerous journals, including the American Journal of Physiology, Archives of General Psychiatry, and the Journal of Neuroscience. He has contributed numerous articles as an author and coauthor to leading scientific journals, including Archives of General Psychiatry, The Journal of Clinical Endocrinology & Metabolism, The Journal of Neuroscience, and Neuropsychopharmacology.
		John M. Kane, MD Professor of Psychiatry, Albert Einstein College of Medicine The Zucker Hillside Hospital John M. Kane, MD is Vice President for Behavioral Health Services of the North Shore - Long Island Jewish Health System and Chairman of Psychiatry at The Zucker Hillside Hospital. He is Professor of Psychiatry, Neurology and Neuroscience and holds the Dr. E. Richard Feinberg Chair in Schizophrenia Research at the Albert Einstein College of Medicine. Dr. Kane received his B.A. from Cornell University and his M.D. from the New York University School of Medicine. He currently directs the NIMH-funded Intervention Research Center for the Study of Schizophrenia at The Zucker Hillside Hospital. He has been a member of the Board of Scientific Counselors for NIMH, and he has served on the council of the American College of Neuropsychopharmacology. He has chaired the NIMH Psychopathology and Psychobiology Review Committee as well as the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration. Dr. Kane is a recipient of the Arthur P. Noyes Award in Schizophrenia, the NAPPH Presidential Award for Research, the American Psychiatric Association Foundations' Fund Prize for Research, the Kempf Fund Award for Research Development in Psychobiological Psychiatry, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists.
		T. Scott Stroup, MD, MPH Associate Professor University of North Carolina at Chapel Hill T. Scott Stroup, MD, MPH is an Associate Professor of Psychiatry at the University of North Carolina at Chapel Hill, where he is also a faculty research fellow at the Cecil G. Sheps Center for Health Services Research and Adjunct Associate Professor of Social Medicine. His clinical base is the Schizophrenia Treatment and Evaluation Program (STEP) at the University of North Carolina Hospitals. He was the co-principal investigator of the National Institute of Mental Health-sponsored Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.
		Michael F. Green, PhD. Professor, Department of Psychiatry and Biobehavioral Sciences Geffen School of Medicine at UCLA, and VA Greater Los Angeles Healthcare System Michael Foster Green, PhD. is a Professor-in-Residence in the Department of Psychiatry and Biobehavioral Sciences at the Geffen School of Medicine at UCLA, and is Director of the Treatment Unit of the Department of Veteran Affairs VISN 22 Mental Illness Research, Education, and Clinical Center (MIRECC). Dr. Green obtained his B.A. in psychobiology at Oberlin College, his doctorate in neuropsychology at Cornell University, and his postdoctoral training in neuropsychology at UCLA. He is on the editorial boards of Cognitive Neuropsychiatry, Schizophrenia Research, and Schizophrenia Bulletin and has authored over 130 journal articles. He has received numerous grants from NIMH, the Veterans Administration, and private foundations. His research activities have been devoted to understanding the nature and implications of cognitive dysfunction in schizophrenia, including neurocognitive indicators of genetic vulnerability to schizophrenia and neural mechanisms of cognitive dysfunction. His laboratory has explored the relationship between cognitive deficits in schizophrenia and activities of daily living, and the neurocognitive effects of antipsychotic and adjunctive medications. He has written two books: Schizophrenia from a Neurocognitive Perspective: Probing the Impenetrable Darkness, published in 1998, and Schizophrenia Revealed: From Neurons to Social Interactions, published in 2001. Dr. Green is currently president of the Society for Research in Psychopathology.
		Lawrence Blonde, MD, FACP, FACE Director, Ochsner Diabetes Clinical Research Unit Section on Endocrinology, Diabetes and Metabolism Ochsner Clinic Foundation New Orleans, LA Lawrence Blonde, MD, FACP, FACE, is director of the Ochsner Diabetes Clinical Research Unit in the Section on Endocrinology, Diabetes and Metabolism, and Associate Residency Program Director in the Department of Internal Medicine at the Ochsner Clinic Foundation in New Orleans, Louisiana. Dr. Blonde’s clinical and research activities have focused on patients with diabetes mellitus and investigations of new therapies and healthcare delivery systems for them. He has also published and presented information about the use of computers to enhance medical education and patient care. Dr. Blonde is a member of the Board of Directors of the American Association of Clinical Endocrinologists (AACE). He has chaired the AACE Electronic Medical Records Task Force and was the co-chair for the AACE Consensus Conference for the Implementation of Outpatient Management of Diabetes Mellitus. Dr. Blonde is a member of the Executive Committee and chair of the Operations Committee of the National Diabetes Education Program, representing the American College of Physicians (ACP) and is chair of the American Diabetes Association (ADA) Doing Better Committee. Dr. Blonde is a member of the Board of Directors of the Council for the Advancement of Diabetes Research and Education (CADRE) and is a member of the National Quality Forum Adult Diabetes Care Consensus Maintenance Committee. Dr. Blonde is a former member of the board of directors of the American Diabetes Association and is a current member and former chair of the ADA Professional Practice Committee, which develops practice guidelines for the care of people with diabetes.
	*Disclosure Policy* It is the policy of The Semel Institute at UCLA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty/authors/planners participating in our programs are expected to disclose any relevant relationships they may have with the commercial companies. These relationships, along with the educational content of this program, have been reviewed and any potential conflicts of interest have been resolved to the satisfaction of the Semel Institute at UCLA. *Faculty Disclosure Declarations* John W. Newcomer, MD – Grant Support, Consultant for: Janssen Pharmaceutica, Pfizer, Inc., Bristol-Myers Squibb Grant Support for The National Institute of Mental Health (NIMH), The National Alliance for Research on Schizophrenia and Depression (NARSAD), Sidney R. Baer Foundation Consultant for: AstraZeneca Pharmaceuticals, GlaxoSmithKline, Organon, Wyeth John M. Kane, MD – Consultant, Speakers Bureau for: Bristol-Myers Squibb, Janssen Pharmaceutica Consultant for: Pfizer, Inc, Abbott Laboratories, Wyeth, Eli Lilly and Company T. Scott Stroup, MD, MPH – Consultant for: Pfizer, Inc., Eli Lilly and Company, GlaxoSmithKline Michael F. Green, PhD – Consultant for: Bristol-Myers Squibb, Otsuka, Eli Lilly and Company, Pfizer, Inc, Sanofi-Aventis, Memory, Abbott Laboratories Lawrence Blonde, MD, FACP, FACE – Consultant, honoraria, and grants/research support for: Amilyn Pharmaceuticals, AstraZeneca, Aventis, BD, Bristol-Myers Squibb, Eli Lilly and Company, EMD, GlaxoSmithKline, Merck & Co., Inc., Novo-Nordisk, Novartis Pharmaceuticals Corporation, Pfizer, Inc, Sanofi-Aventis Consultant and honoraria for: Lifescan, Merck/Schering-Plough, Abbott Laboratories Honoraria for: Takeda Pharmaceuticals of America, Wyeth Dr. Blonde’s spouse owns shares of Amylin Pharmaceuticals and Pfizer in an inherited account that is not part of their community property. Peter Fahnestock, MD – Grant/Research Support for: Bristol-Myers Squibb Consultant for: Shire Printer settings may vary. Please use landscape layout option. Copyright © 2006 ArcMesa Educators / CMEdiscovery.com. All rights reserved. .